Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status

By                          

Oncology Letters, Vol. 3, Iss. 2, 2012-01 ,pp. : 425-428

Spandidos Publications

Access to resources Recommend Favorite

Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

By Pernot Simon   Mitry Emmanuel   Samalin Emmanuelle   Dahan Laetitia   Dalban Cécile   Ychou Marc   Seitz Jean-François   Turki Hajer   Mazard Thibault   Zaanan Aziz   Lepère Céline   Vaillant Jean-Nicolas   Landi Bruno   Rougier Philippe   Taieb Julien  

Gastric Cancer, Vol. 17, Iss. 2, 2014-04 ,pp. : 341-347

Springer Publishing Company

Access to resources Recommend Favorite

The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma

By Özdemir Nuriye   Abalı Hüseyin   Öksüzoğlu Berna   Budakoglu Burçin   Uncu Doğan   Güler Tunç   Odabaşı Hatice   Zengin Nurullah  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 680-684

Humana Press, Inc

Access to resources Recommend Favorite

Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer

By Viteri Ainhoa   Muñoz Alberto   Rubio Itziar   Barceló Ramón   Martínez-Bueno Alejandro   Fernández Ricardo   Carrera Sergio   López-Vivanco Guillermo  

Acta Oncologica, Vol. 46, Iss. 3, 2007-01 ,pp. : 397-399

Informa Healthcare

Access to resources Recommend Favorite

Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer

By Hori Natsuko  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 435-438

Springer Publishing Company

Access to resources Recommend Favorite